Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is...
Restructuring and Survival Signals: How 10 Off-the-Radar Stocks Are Navigating the Capital Pivot
12 Health Care Stocks Moving In Wednesday's Intraday Session
11 Health Care Stocks Moving In Thursday's Intraday Session
Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watch
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering | ELTX Stock News
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes